Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Tricida, Inc.
  6. Summary
    TCDA   US89610F1012

TRICIDA, INC.

(TCDA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
4.34(c) 4.47(c) 4.43(c) 4.6(c) 4.58 Last
86 289 36 815 110 801 110 727 73 880 Volume
0.00% +3.00% -0.89% +3.84% -0.43% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -156 M - -
Net Debt 2021 13,9 M - -
P/E ratio 2021 -1,65x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -159 M - -
Net Debt 2022 149 M - -
P/E ratio 2022 -1,94x
Yield 2022 -
Capitalization 231 M 231 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 64
Free-Float 97,3%
More Financials
Company
Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts... 
More about the company
Ratings of Tricida, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about TRICIDA, INC.
09/15TRICIDA : Investor Presentation, September 2021
PU
09/07TRICIDA : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AQ
08/31TRICIDA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
08/31Tricida, Inc. and Patheon Austria GMBH & Co KG Enter an Amendment to Certain Terms of t..
CI
08/16TRICIDA, INC. : Other Events (form 8-K)
AQ
08/09TRICIDA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA..
AQ
08/09TRICIDA, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
08/09TRICIDA : Announces Second Quarter 2021 Financial Results
AQ
08/09Tricida, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/28TRICIDA : to Report Second Quarter Financial Results and Host Conference Call and Webcast ..
AQ
06/25TRICIDA, INC.(NASDAQGS : TCDA) dropped from Russell 2000 Dynamic Index
CI
06/25TRICIDA, INC.(NASDAQGS : TCDA) dropped from Russell 2000 Index
CI
06/25TRICIDA, INC.(NASDAQGS : TCDA) added to Russell Microcap Growth Index
CI
06/25TRICIDA, INC.(NASDAQGS : TCDA) dropped from Russell 3000 Index
CI
06/25TRICIDA, INC.(NASDAQGS : TCDA) added to Russell Microcap Index
CI
More news
News in other languages on TRICIDA, INC.

- No features available -

More news
Chart TRICIDA, INC.
Duration : Period :
Tricida, Inc. Technical Analysis Chart | TCDA | US89610F1012 | MarketScreener
Technical analysis trends TRICIDA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 4,58 $
Average target price 15,00 $
Spread / Average Target 228%
EPS Revisions
Managers and Directors
Gerrit Klaerner President, Chief Executive Officer & Director
Geoffrey M. Parker Executive VP, Chief Operating & Financial Officer
Klaus R. Veitinger Chairman
Wilhelm Stahl Chief Technology Officer & Executive VP
Dawn Parsell Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
TRICIDA, INC.-35.04%232
MODERNA, INC.267.77%165 027
LONZA GROUP AG26.86%57 923
IQVIA HOLDINGS INC.34.84%47 547
CELLTRION, INC.-26.60%31 003
SEAGEN INC.-7.85%29 566